Selected Grants
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated with Epidiolex (Cannabidiol) Oral Solution
Clinical TrialPrincipal Investigator · Awarded by GW Research Limited · 2021 - 2031AN OPEN-LABEL, MULTICENTER, OUTPATIENT EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZU
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma · 2025 - 202820-Week Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants with Dravet Syndrome (ARGUS
Clinical TrialPrincipal Investigator · Awarded by Epygenix Therapeutics, Inc. · 2025 - 2028Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut
Clinical TrialPrincipal Investigator · Awarded by Epygenix Therapeutics, Inc. · 2025 - 2028BEELINE: a Phase 1b/3 Study in GRIN-related neuro disorder
Clinical TrialPrincipal Investigator · Awarded by GRIN Therapeutics, Inc. · 2025 - 2028NS-PEACE Neonatal Seizures -Predicting Epilepsy and Assessing Comparative Effectiveness
ResearchPrincipal Investigator · Awarded by Weill Cornell Medicine · 2023 - 2028STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma · 2025 - 2027Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures"
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2022 - 2026A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic- Clonic Seizures
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2023 - 2026A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients with Dravet Syndrome.
Clinical TrialPrincipal Investigator · Awarded by Stoke Therapeutics, Inc. · 2025 - 2026A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Carisbamate (Ykp509) As Adjunctive Treatment For Seizures Associated With Lennox-Gastaut Syndrome In Children And Adults, With Optional Open-Label Extensio
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2023 - 2026Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizure
Clinical TrialPrincipal Investigator · Awarded by Xenon Pharmaceuticals Inc. · 2025 - 2026An open-label, long-term safety and tolerability study of b1ivaracetam as adjunctive treatment in pediatric study participants with epilepsy
Clinical TrialPrincipal Investigator · Awarded by UCB Biopharma · 2021 - 2026A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study Of Cenobamate (YKP3089) In Pediatric Subjects With Partial Onset Seizures
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2021 - 2025A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2023 - 2025YKP3089C025
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2022 - 2025Study of Oral Pyridoxal 5'-Phosphate for the Treatment of Patients with PNPO Deficiency
Clinical TrialPrincipal Investigator · Awarded by Medicure, Inc. · 2021 - 2025Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep
Clinical TrialPrincipal Investigator · Awarded by Neurocrine Biosciences, Inc. · 2022 - 2025Marinus 1042 TSC 3002 GNX Treatment
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2023 - 2025AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETICS STUDY OF VALTOCO® WITH OPEN-LABEL SAFETY PERIOD IN PEDIATRIC SUBJECTS WITH EPILEPSY
Clinical TrialPrincipal Investigator · Awarded by Neurelis, Inc · 2022 - 2025LivaNova Core Registry
Clinical TrialPrincipal Investigator · Awarded by LivaNova · 2019 - 2025Hartwell Individual Biomedical Research Award
ResearchCo Investigator · Awarded by Hartwell Foundation · 2021 - 2024Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wav
Clinical TrialPrincipal Investigator · Awarded by Neurocrine Biosciences, Inc. · 2021 - 20231042-TSC-2001 - Marinus TSC
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2020 - 2023Phase I, Open-Label Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2020 - 2023An Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome (Pro00102865)
Clinical TrialPrincipal Investigator · Awarded by Stoke Therapeutics, Inc. · 2019 - 2023A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2019 - 2023Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy
Clinical TrialPrincipal Investigator · Awarded by LivaNova · 2019 - 2022Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome
Clinical TrialPrincipal Investigator · Awarded by SK Life Science, Inc · 2019 - 2022OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN PEDIATRIC SUBJECTS WITH EPILEPSY
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2018 - 2022E2007-G000-238 Perampanel for <2 yrs
Clinical TrialPrincipal Investigator · Awarded by Eisai, Inc. · 2019 - 2022A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
Clinical TrialPrincipal Investigator · Awarded by Bio-Pharm Solutions Co., Ltd. · 2020 - 2021A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS ¿1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY PHASE 2
Clinical TrialPrincipal Investigator · Awarded by UCB Pharma, Inc. · 2018 - 2021A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >1 MONTH TO <4 YEARS OF AGE WITH PARTIAL-ONSET SEIZURES
Clinical TrialPrincipal Investigator · Awarded by UCB Biosciences Inc. · 2019 - 2021A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS WITH EPILEPSY WITH PARTIAL-ONSET SEIZURES PHASE 3
Clinical TrialPrincipal Investigator · Awarded by UCB Biosciences Inc. · 2019 - 2020A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2018 - 2020A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS)
Clinical TrialPrincipal Investigator · Awarded by Zogenix International Limited · 2019 - 2020A Retrospective Multicenter Study to Investigate Dosage, Efficacy,and Safety of Fycompa® in Routine Clinical Care of Patients With Epilepsy
ResearchPrincipal Investigator · Awarded by Eisai, Inc. · 2018 - 2019External Relationships
- LivaNova, Inc.
- Pyros Pharmac
- SK Life Sciences
- Takeda Pharmaceutical Co. Ltd.
- UCB Biopharma SPRI
- Zoll
- neuralis
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.